donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > ASND Ascendis Pharma A/S > Detailed Quotes

ASND Ascendis Pharma A/S

110.230
+5.420+5.17%
Close 08/12 16:00 ET
110.23000.00%
Post Mkt Price 08/12 16:30 ET
High
110.390
Open
105.980
Turnover
56.25M
Low
103.285
Pre Close
104.810
Volume
519.85K
Market Cap
6.15B
P/E(TTM)
Loss
52wk High
178.710
Shares
55.81M
P/E(Static)
Loss
52wk Low
61.579
Float Cap
4.76B
Bid/Ask %
0.00%
Historical High
183.980
Shs Float
43.19M
Volume Ratio
0.48
Historical Low
11.920
Dividend TTM
--
Div Yield TTM
200
P/B
8.96
Dividend LFY
--
Div Yield LFY
181.44%
Turnover Ratio
1.20%
Amplitude
6.78%
Avg Price
108.194
Lot Size
1
Float Cap
4.76B
Bid/Ask %
0.00%
Historical High
183.980
Shs Float
43.19M
Volume Ratio
0.48
Historical Low
11.920
Dividend TTM
--
P/B
8.96
Dividend LFY
--
Turnover Ratio
1.20%
Amplitude
6.78%
Avg Price
108.194
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
CEO: Mikkelsen, Jan Moller
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...